Streetbeat News

Products Services

ARWR

Arrowhead Pharmaceuticals has filed for regulatory clearance to initiate a Phase 1 clinical trial of ARO-SOD1, an RNAi-based investigational medicine for treating amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations. ARO-SOD1 is the first therapeutic candidate leveraging Arrowhead's TRiM platform for CNS delivery.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:35 am

HLNE

TIFIN and Hamilton Lane (HLNE) are partnering to launch an AI-powered investment assistant for private markets, aiming to provide personalized investment recommendations and insights.

Portfolio Pulse from Bill Haddad

June 27, 2023 | 11:35 am

SNY

Sanofi's Phase 2b study of amlitelimab for adults with moderate-to-severe atopic dermatitis met its primary endpoint, showing statistically significant improvements in symptoms. This marks the 5th positive outcome for Sanofi's pipeline since 2023. Amlitelimab was well-tolerated, and no new safety issues were detected.

Portfolio Pulse from Vandana Singh

June 27, 2023 | 11:34 am

ENVX

Enovix has received a purchase order to produce battery cells for the US Army. The size of the order has not been disclosed.

Portfolio Pulse from Bill Haddad

June 27, 2023 | 11:33 am

ANVS

Annovis Bio, a clinical stage drug platform company, has announced the creation of a novel crystalline form of buntanetap (ANVS402) and filed a new composition of matter provisional patent with the U.S. Patent and Trademark Office.

Portfolio Pulse from Bill Haddad

June 27, 2023 | 11:32 am

U

Unity (NYSE:U) has launched a dedicated AI marketplace in the Unity Asset Store, featuring curated solutions to accelerate AI-driven game development and gameplay enhancements. The marketplace centralizes AI tools, including Unity Verified Solutions, community-built solutions, and emerging AI technologies.

Portfolio Pulse from Charles Gross

June 27, 2023 | 11:27 am

ACIU

AC Immune's stock is trading higher after the FDA granted fast track designation for its anti-amyloid-beta active immunotherapy, ACI-24.060, for Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:16 am

BDTX

Black Diamond Therapeutics announced initial dose escalation data showing anti-tumor activity of BDTX-1535 in non-small cell lung cancer patients across multiple EGFR mutation families.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:12 am

FWBI

First Wave BioPharma has announced the publication of two patent applications for the composition of matter and methods of use claims governing its enhanced enteric microgranule delivery formulation of Adrulipase.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:11 am

BIIB

Alcyone Therapeutics announced a collaboration with Biogen for a pivotal FDA-approved trial of Alcyone's ThecaFlex DRx System to assess repeat intrathecal access, cerebrospinal fluid aspiration, and delivery of Spinraza (Nusinersen).

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:09 am